Rethinking Vaccine Communications: The Key to Reopening Society
In the last week, Pfizer/BioNTech and Moderna both announced results from two COVID-19 Phase 3 clinical trials showing efficacy of greater than 90 percent. According to company press releases, the trials showed no significant safety issues. (Full publication of the...